Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Continuous net settlement (CNS)

Method of securities clearing and settlement using a clearing house, which matches transactions to securities available, resulting in one net receive or deliver position at the end of the day.

Continuous Net Settlement

A clearing practice in which all buy and sell orders are settled within a brokerage firm. That is, all buy and sell orders are offset against each other on a particular trading day, such that only orders that are "left over" remain to be settled. This results in fewer securities needing to be moved into or out of a particular brokerage.


References in periodicals archive ?
Figure 68: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Market Drivers and Restraints, 2010-2017 109
The medical-surgical CNS assesses the nature of the problem and develops a comprehensive plan to get LOS in line with national norms, thus returning the service line to financial viability.
Because the CNS has a macrophage-inhibiting molecule, the myelin cleanup process doesn't proceed efficiently there, and nerve cell regeneration stalls, asserts Schwartz.
The report begins with an introduction to CNS disorders.
CNS Lymphoma Therapeutic Products under Development, Key Players in CNS Lymphoma Therapeutics, CNS Lymphoma Pipeline Overview, CNS Lymphoma Pipeline, CNS Lymphoma Pipeline Assessment
Hans Thoenen and Martin Schwab of the Max Planck Institute for Psychiatry in Martinsried, West Germany, propose that the CNS contains substances that inhibit nerve outgrowth.
The CNS Summit gathers leading stakeholders with the goal of producing concrete results that shape the future of CNS drug development.
Summary GlobalData's clinical trial report, "AIDS - Related Primary CNS Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the AIDS - Related Primary CNS Lymphoma clinical trial scenario.
Knowledge to help your work and save time, helping your influence Our report strives to help your business research, analyses, and decisions on treatments for debilitating CNS diseases.
com/research/1fc188/transdermal_cns_th) has announced the addition of the "Transdermal CNS Therapeutics: Products, Pipeline Candidates, Markets, Forecasts" report to their offering.
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment